Traws Pharma, Inc. Overview
Pro stress-test →Traws Pharma is a clinical-stage biopharmaceutical company developing novel therapies targeting respiratory viral diseases, integrating antiviral drug development with medical intelligence and regulatory strategy. The company made significant progress advancing a next-generation influenza antiviral, supported by $60M in new financing.
Strategic Profile
Pro stress-test →The company is developing investigational therapies including Tivoxavir marboxil (an endonuclease inhibitor for bird flu and seasonal influenza treatment) and TRX01/Ratutrelvir (an inhibitor for COVID-19). However, in June 2026, the planned Phase 2a human influenza challenge study of tivoxavir marboxil was deferred due to a negative review by the UK's Medicines and Healthcare Products Regulatory Agency (MHRA).
Competitive Landscape
Pro stress-test →Analysts note Traws offers an alternative to Cidara's CD388 in the antiviral space. Traws competes in the narrow but high-stakes respiratory viral disease therapeutics market, facing competition from larger pharma companies and specialized biotech focused on influenza, avian flu, and COVID-19 treatments. The regulatory environment and clinical trial timelines create differentiation pressure.
Industry Context
Traws Pharma, Inc. operates in Antiviral therapeutics development.
Key facts
Headquarters: Newtown, PA · Market cap: $12.7M